Raymond James Maintains Strong Buy on Flexion Therapeutics, Raises Price Target to $28

Raymond James analyst Elliot Wilbur maintains Flexion Therapeutics (NASDAQ:FLXN) with a Strong Buy and raises the price target from $25 to $28.

Benzinga · 12/27/2019 12:27

Raymond James analyst Elliot Wilbur maintains Flexion Therapeutics (NASDAQ:FLXN) with a Strong Buy and raises the price target from $25 to $28.